Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | CARTITUDE-1: outcomes of patients with triple-class exposed multiple myeloma treated with cilta-cel

Michel Delforge • 13 May 2023
COMy 2023
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1

Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, gives an overview of the results obtained from the CARTITUDE-1 trial (NCT03548207), highlighting the promising response rates observed in patients with triple-class exposed myeloma treated with ciltacabtagene autoleucel (cilta-cel). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michel Delforge

2:20
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3
Michel Delforge • 10 Dec 2023
2:16
Moving CAR-T therapy into the frontline setting in myeloma: insights into CARTITUDE-5 & CARTITUDE-6
Michel Delforge • 4 Oct 2023
1:50
How might inequalities in access to CAR-T therapy for multiple myeloma be addressed?
Michel Delforge • 4 Oct 2023
8:28
Treatment selection for patients with multiple myeloma at first relapse and beyond
Michel Delforge • 4 Oct 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals